The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 08, 2024
Filed:
May. 09, 2022
Applicant:
Cortexyme, Inc., South San Francisco, CA (US);
Inventors:
Andrei W. Konradi, Burlingame, CA (US);
Robert A. Galemmo, Jr., South San Francisco, CA (US);
Stephen S. Dominy, Novato, CA (US);
Casey C. Lynch, San Francisco, CA (US);
Leslie J. Holsinger, Los Altos, CA (US);
Assignee:
Lighthouse Pharmaceuticals, Inc., San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 233/62 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/41 (2006.01); A61K 31/42 (2006.01); A61K 31/44 (2006.01); A61K 31/4402 (2006.01); A61K 31/4406 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); A61K 31/505 (2006.01); A61K 31/513 (2006.01); A61K 31/655 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 31/04 (2006.01); C07B 59/00 (2006.01); C07C 233/78 (2006.01); C07C 235/10 (2006.01); C07C 235/50 (2006.01); C07C 237/42 (2006.01); C07C 245/08 (2006.01); C07C 247/16 (2006.01); C07C 247/18 (2006.01); C07C 317/28 (2006.01); C07C 323/40 (2006.01); C07C 323/42 (2006.01); C07C 381/00 (2006.01); C07D 213/65 (2006.01); C07D 213/68 (2006.01); C07D 213/70 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 239/34 (2006.01); C07D 239/36 (2006.01); C07D 239/38 (2006.01); C07D 257/04 (2006.01); C07D 261/12 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07F 5/02 (2006.01);
U.S. Cl.
CPC ...
C07C 233/62 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/41 (2013.01); A61K 31/42 (2013.01); A61K 31/44 (2013.01); A61K 31/4402 (2013.01); A61K 31/4406 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/655 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 31/04 (2018.01); C07B 59/001 (2013.01); C07C 233/78 (2013.01); C07C 235/10 (2013.01); C07C 235/50 (2013.01); C07C 237/42 (2013.01); C07C 245/08 (2013.01); C07C 247/16 (2013.01); C07C 247/18 (2013.01); C07C 317/28 (2013.01); C07C 323/40 (2013.01); C07C 323/42 (2013.01); C07C 381/00 (2013.01); C07D 213/65 (2013.01); C07D 213/68 (2013.01); C07D 213/70 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 239/34 (2013.01); C07D 239/36 (2013.01); C07D 239/38 (2013.01); C07D 257/04 (2013.01); C07D 261/12 (2013.01); C07D 401/12 (2013.01); C07D 413/12 (2013.01); C07F 5/02 (2013.01); C07C 2601/08 (2017.05);
Abstract
The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated withinfection, including brain disorders such as Alzheimer's disease.